Vasopressin dose in variseal bleeding in chronic liver disease
Reading File
Now I'll search the medical library and PubMed in parallel for vasopressin dosing in variceal bleeding.
Finding Sources
Searching PubMed
vasopressin terlipressin variceal bleeding portal hypertension
Good results. Let me now read the key textbook sections for dosing details.
Reading File
Reading File
I now have comprehensive textbook data. Here is the full clinical answer:
Vasopressin & Analogs in Variceal Bleeding — Dosing & Clinical Use
Vasopressin (ADH)
Mechanism: Potent splanchnic vasoconstrictor → reduces portal and collateral blood flow. Compared to placebo, vasopressin stopped bleeding in 52% vs 18% of patients, but rebleeding rates were as high as 45%.
| Parameter | Details |
|---|---|
| Route | Continuous IV infusion |
| Dose | 0.2–0.4 U/min, can be increased up to 0.8 U/min |
| Duration | 24 hours maximum |
| Mandatory adjunct | Nitroglycerin IV starting at 50 mcg/min (max 400 mcg/min), titrated to maintain SBP ~90 mmHg |
Nitroglycerin is mandatory alongside vasopressin to counteract coronary artery constriction, prevent cardiac events, and reduce intrahepatic/collateral resistance.
Serious adverse effects of vasopressin alone:
- Bowel ischemia
- Hypertension
- Myocardial ischemia
- Cardiac arrhythmia
- Cardiac failure
Because of these significant side effects, vasopressin is seldom used in modern practice — it is largely replaced by terlipressin (where available) or octreotide.
Terlipressin (Synthetic Vasopressin Analog — Preferred)
Longer-acting, safer profile than vasopressin, and the only vasoactive agent shown to reduce mortality at 2 and 6 weeks in acute variceal bleeding (34% relative risk reduction in overall mortality vs placebo).
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Initial control | 2 mg IV bolus | Every 4 hours | First 48 hours |
| Maintenance | 1 mg IV bolus | Every 4 hours | Up to 5 days total |
Adverse effects: arrhythmias, angina, limb ischemia (~2–4% of patients).
Comparative Agents (for context)
| Agent | Dose | Duration |
|---|---|---|
| Octreotide (preferred in USA) | 50 mcg IV bolus → 50 mcg/hr infusion | 3–5 days |
| Somatostatin | 250 mcg IV bolus → 250–500 mcg/hr infusion | 5 days |
Meta-analysis shows octreotide is more effective than vasopressin in achieving hemostasis, with a far superior safety profile. Octreotide is the drug of choice in the United States; terlipressin is preferred in Europe and South Asia.
Key Clinical Points
- Start vasoactive therapy immediately upon suspicion of variceal bleeding — even before endoscopy, ideally in the ED.
- Combine vasoactive drugs with endoscopic variceal ligation (EVL) and antibiotic prophylaxis (reduces infection rate by >50%).
- Vasopressin must never be given without concomitant nitroglycerin due to cardiac risk.
- Vasoactive drugs are continued for 2–5 days post-endoscopy to reduce early rebleeding.
Sources:
- Mulholland and Greenfield's Surgery, 7e, Table 59.15 (AASLD 2016 Practice Guidance–adapted)
- Yamada's Textbook of Gastroenterology, 7e, Vasoactive drug therapy section
- Sleisenger and Fordtran's GI and Liver Disease, Medical Management of Acute Variceal Bleeding
This is a shared conversation. Sign in to Orris to start your own chat.